Please assess the completion status of the following clinical trial:

Trial Title: Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current BPD I, II or NOS and cocaine or alcohol use disorder with HAMD score of ≥ 15~* Cocaine or alcohol use with 5 days of initiating study drug~* Men and women~* Age 18-70 years~Exclusion Criteria:~* Psychotic features~* Non-English speakers~* Treatment resistant depression defined as failure of a trial of antidepressants (≥ 4 weeks at a therapeutic dose) in current episode~* Major medical condition including heart, lung, liver or renal disease, cancer, neurological or immunological conditions~* Vulnerable populations including prisoners, cognitively impaired individuals, and pregnant or nursing women~* Prior side effects or allergic reactions to icariin-containing preparations~* Change in psychotropic medications within 14 days of study entry~* Current suicidal ideation (plan and intent), a suicide attempt within the past 12 months or history of \> 1 lifetime suicide attempt

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- icariin (Type: EXPERIMENTAL): Icariin will be given 100 mg/day. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 for participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.

Based on this trial design, predict the completion outcome and termination type (if applicable).